Bio-Techne (TECH)
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
NASDAQHealth CareBiotechnologySnapshot 2026-10-29
Research Workspace
Put TECH beside peers and holdings, graph the same metric, and keep your notes with the evidence.
Daily closes. Earnings/event dots are placed inline.
Industries move in repeating boom-and-bust cycles. This shows where this stock’s industry sits in that cycle, stage by stage (recovery → expansion → supercycle → steady → deceleration → contraction), from its fundamentals (orders, revenue, capital spending), not the stock’s price.
A booming industry is a tailwind for the names in it; a contracting one is a headwind. Companies in the same industry tend to rise and fall together with the cycle, the way a tide lifts and lowers every boat in the harbor at once, so a large part of a stock’s swing can come from where its industry sits rather than from the company itself. It’s context for reading the company’s results, not a buy/sell call. Full explanation →
Life Sciences Tools & Services: structurally weak cohort (structural / late-cycle), so the cyclical early-warning is suppressed.
The stage band shows the industry’s cycle over the chart’s timeline (each color a stage); a ▼ marks a quarter its growth inflected down — amber is an unconfirmed watch, red is confirmed the next quarter. Use “Overlay cycle on chart” to tint the price chart by stage. The industry’s fundamentals, not a signal on this stock.
Management is running behind on a stated commitment.
View ThesisRanks among the strongest in its industry on quality — around the top 20%.
View QualityManagement screens strong on capital allocation, earnings delivery, margins, the balance sheet.
View ManagementExpectations look high — the market is pricing in about 50% growth a year, above the roughly 9% analysts expect, leaving little room for error.
View ValuationThis stock is volatile — it swings about 0% on a typical day and fell roughly 39% in its worst 12-month stretch.
View RiskTECH’s thesis rests on strong recent performance, but revenue growth remains weak, with the latest quarter up 1% year over year. The fourth-quarter fiscal 2026 result beat non-GAAP EPS consensus by 13%. TECH trades at 40× P/E versus a 37× peer median, yet the market prices more growth than our forecast. Its elevated valuation and management’s delayed commitment create specific risks. Our model puts the next-quarter miss probability near 30%. Peer multiples imply a price about 50% below where it trades (it looks expensive on this basis). The thesis is on watch. This read is provisional.
Trailing returns as of 2026-10-29. TECH is total return (includes dividends); the S&P 500 benchmark is price return (the index excludes dividends).
Based on 14 analysts currently covering TECH (as of Oct 2026).
Analyst ratings and price targets are third-party Wall Street estimates, not QuarterlyIQ’s view. Not investment advice.
Continue this research
Compare TECH with peers and holdings, graph the same reported metric, keep your questions beside the evidence, and return when the facts change.
Compare now without an account. Saving and monitoring require an account.
| Compare | Company | Living FV | P/E | Revenue % | Quality |
|---|---|---|---|---|---|
| TECH Selected company | Graph | Compare | Trend | Review | |
| Peer Add a competitor | Graph | Compare | Trend | Review | |
| Holding Compare a holding | Graph | Compare | Trend | Review |
Selected metric trend
Quarterly · checked companies · value or % of revenue
A consensus fair price across 10 valuation methods, at three horizons. As of 2026-10-29. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
Today's peer multiple on trailing earnings, with no growth credited. This is the headline read.
Adds projected growth, so it leans optimistic by design. Read it as upside context, not a base case.
A price-focused, side-by-side fair-value read versus Life Sciences Tools & Services — fair value, gap to price, and forward P/E.
Compare the value case
Put TECH next to peers and holdings, compare Living FV and multiples, then graph the driver behind the difference.
Shareholder lawsuit may impact management's focus and resources.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
End-of-day figures as of 2026-10-29. EPS is implied from price ÷ P/E. Not investment advice.
A long-thesis check that carries the widest uncertainty of the three horizons.
Direction of the business behind the multiple. Bands are backend reads; trailing-12-month basis.

Advances: Achieve revenue growth
Earnings and revenue growth support management's growth objective.

Advances: Achieve revenue growth
In-line earnings and revenue beat support growth objectives.

Advances: Achieve revenue growth
Expansion supports revenue growth through innovative product offerings.

Acquisition enhances growth potential and market position.
Advances: Achieve revenue growth
Acquisition enhances growth potential and market position.
Acquisition enhances growth potential and market position.
Acquisition enhances growth potential and market position.